Followers | 4053 |
Posts | 151254 |
Boards Moderated | 4 |
Alias Born | 08/05/2009 |
Thursday, February 06, 2020 8:26:44 PM
CAMBRIDGE, MA., February 6, 2020 – Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper limb paralysis, today announced preliminary financial and operational results for the fourth quarter and fiscal year ended December 31, 2019.
Key Preliminary Results for Q4 and 2019
•
Revenue for the fourth quarter is expected to be in a range of $1.4M-$1.5M, representing an increase of between 57% and 69% over the prior year fourth quarter revenue of approximately $890,000 and compared to third quarter revenue of approximately $607,000. For the full year, revenue is expected to be in the range of $3.7M-$3.8M, an increase of between 52% and 55% compared to the prior year’s revenue of approximately $2.4M.
•
The Company’s reimbursement pipeline grew to 594 MyoPro units at December 31, 2019, including 193 new additions to the pipeline during the fourth quarter resulting from the Company’s digital marketing activity and larger distributor base in Europe. The number of MyoPro units in the reimbursement pipeline at the end of the third quarter 2019 was 528.
•
As of December 31, 2019, we had 331 direct billing candidates, accounting for 56%, of the MyoPro pipeline, with 81% of the new candidates entering the pipeline in the fourth quarter to be billed directly to the payers by Myomo.
•
As of December 31, 2019, the backlog of authorized MyoPro units in the process of being delivered and awaiting insurance payments stood at 53 units, reflecting a higher number of revenue units in the fourth quarter compared to each of the prior three quarters of 2019.
•
Cash on hand as of December 31, 2019 was approximately $4.5M. Cash burn in the fourth quarter was approximately $2.7M. Cash burn in the fourth quarter was affected by advance payments made to a subcontracted manufacturing partner for subassemblies needed to fulfill expected orders in calendar year 2020.
This financial data as of and for the quarter and year ended December 31, 2019 is preliminary and may change, and is based on information available to management as of the date hereof and is subject to completion by management of our financial statements as of and for the quarter and year ended December 31, 2019. There can be no assurance that our final results of operations for these periods or cash position as of December 31, 2019 will not differ from these estimates, including as a result of review adjustments and any such changes could be material. Our
independent registered public accountants have not audited, reviewed or performed any procedures with respect to such preliminary financial data and accordingly do not express an opinion or any other form of assurance with respect thereto. These results could change as a result of further review. Complete quarterly results and annual results will be included in our Annual Report on Form 10-K for the year ended December 31, 2019.
Recent MYO News
- Myomo to Report First Quarter Financial Results on May 8, 2024 • Business Wire • 05/01/2024 09:21:00 PM
- Myomo Appoints Heather Getz to its Board of Directors • Business Wire • 03/28/2024 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 12:05:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 11:50:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:10:10 PM
- Myomo Reports Fourth Quarter and Full Year 2023 Financial Results • Business Wire • 03/07/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:21:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 12:12:22 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 01:15:14 PM
- CMS Posts Final Medicare DMEPOS Fee Schedule Rate for the MyoPro® • Business Wire • 03/01/2024 01:00:00 PM
- Myomo to Report Fourth Quarter Financial Results on March 7, 2024 • Business Wire • 02/29/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 09:54:33 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 03:42:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2024 11:34:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/02/2024 10:12:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 10:06:58 PM
- Myomo Announces Closing of $6 Million Registered Direct Offering of Common Stock Priced At-the-Market • Business Wire • 01/19/2024 09:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:20:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/17/2024 09:11:11 PM
- Myomo Announces $6 Million Registered Direct Offering of Common Stock Priced At-the-Market • Business Wire • 01/17/2024 01:05:00 PM
- Myomo Reports Preliminary Fourth Quarter Revenue and Backlog • Business Wire • 01/17/2024 01:00:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 01/12/2024 10:43:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 11:03:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/02/2024 10:47:27 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM